CGEM vs. CABA, CRGX, HLVX, RGNX, PRME, PROK, IMTX, RLAY, ALLO, and NVAX
Should you be buying Cullinan Oncology stock or one of its competitors? The main competitors of Cullinan Oncology include Cabaletta Bio (CABA), CARGO Therapeutics (CRGX), HilleVax (HLVX), REGENXBIO (RGNX), Prime Medicine (PRME), ProKidney (PROK), Immatics (IMTX), Relay Therapeutics (RLAY), Allogene Therapeutics (ALLO), and Novavax (NVAX). These companies are all part of the "biological products, except diagnostic" industry.
Cullinan Oncology (NASDAQ:CGEM) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.
Cabaletta Bio received 44 more outperform votes than Cullinan Oncology when rated by MarketBeat users. However, 77.50% of users gave Cullinan Oncology an outperform vote while only 69.44% of users gave Cabaletta Bio an outperform vote.
Cullinan Oncology has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500.
In the previous week, Cullinan Oncology had 39 more articles in the media than Cabaletta Bio. MarketBeat recorded 43 mentions for Cullinan Oncology and 4 mentions for Cabaletta Bio. Cullinan Oncology's average media sentiment score of 0.55 beat Cabaletta Bio's score of 0.27 indicating that Cullinan Oncology is being referred to more favorably in the media.
Cullinan Oncology presently has a consensus price target of $28.75, suggesting a potential upside of 77.47%. Cabaletta Bio has a consensus price target of $34.33, suggesting a potential upside of 148.97%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Cullinan Oncology.
Cabaletta Bio has lower revenue, but higher earnings than Cullinan Oncology. Cabaletta Bio is trading at a lower price-to-earnings ratio than Cullinan Oncology, indicating that it is currently the more affordable of the two stocks.
86.3% of Cullinan Oncology shares are owned by institutional investors. 8.8% of Cullinan Oncology shares are owned by insiders. Comparatively, 12.3% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cullinan Oncology's return on equity of -32.11% beat Cabaletta Bio's return on equity.
Summary
Cullinan Oncology beats Cabaletta Bio on 8 of the 15 factors compared between the two stocks.
Get Cullinan Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Oncology Competitors List
Related Companies and Tools
